iShares Nasdaq Biotechnology ETF (IBB)
320.74
+0.63 +0.20%
NASDAQ
Jun 23, 20:00
Delayed 2m
USD
IBB Key Stats
| Expense Ratio | 0.47% |
| Share Class Assets Under Management | 9.554B |
| 30-Day Average Daily Volume | Upgrade |
| Net Asset Value | 320.61 |
| Discount or Premium to NAV | 0.04% |
| Turnover Ratio | 18.00 |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
Yahoo06/23 17:00
-
Yahoo06/23 16:44
-
Yahoo06/23 13:36
-
MT Newswires06/23 13:25
-
Yahoo06/23 12:13
-
Yahoo06/23 11:57
-
Yahoo06/23 10:52
-
MT Newswires06/23 09:19
-
Yahoo06/22 16:37
-
Yahoo06/22 14:36
IBB Performance
| Total Return | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|
| 1M | 10.24% | 7.50% | 20 |
| 3M | 11.10% | 10.30% | 27 |
| 6M | 17.90% | 19.13% | 61 |
| 1Y | 22.58% | 19.30% | 28 |
| 3Y | 8.42% | 10.02% | 74 |
| 5Y | 20.21% | 18.23% | 27 |
Returns for periods of 1 year and above are annualized.
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.09% | 0.09% | 0.00 |
| Stock | 99.91% | 99.91% | 0.00 |
| Bond | 0.00 | 0.00 | 0.00 |
| Convertible | 0.00 | 0.00 | 0.00 |
| Preferred | 0.00 | 0.00 | 0.00 |
| Other | 0.00 | 0.00 | 0.00 |
IBB Region Exposure
| Americas | 98.34% |
| North America | 98.34% |
| Latin America | 0.00 |
| Greater Europe | 1.21% |
| United Kingdom | 0.48% |
| Europe Developed | 0.67% |
| Europe Emerging | 0.00 |
| Africa/Middle East | 0.05% |
| Greater Asia | 0.45% |
| Japan | 0.00 |
| Australasia | 0.00 |
| Asia Developed | 0.00 |
| Asia Emerging | 0.45% |
| Market Classification | |
| % Developed Markets | 99.55% |
| % Emerging Markets | 0.45% |
Region breakdown data is calculated by using the long position holdings of the portfolio.
IBB Stock Sector Exposure
| Basic Materials | 0.00 |
| Communication Services | 0.00 |
| Consumer Cyclical | 0.00 |
| Consumer Defensive | 0.00 |
| Energy | 0.00 |
| Financial Services | 0.00 |
| Healthcare | 99.92% |
| Industrials | 0.00 |
| Real Estate | 0.00 |
| Technology | 0.08% |
| Utilities | 0.00 |
IBB Stock Market Capitalization
| Giant | 16.37% |
| Large | 42.24% |
| Medium | 17.56% |
| Small | 13.97% |
| Micro | 9.87% |
IBB Stock Style Exposure
| Large Cap Value | 10.32% |
| Large Cap Blend | 16.34% |
| Large Cap Growth | 33.67% |
| Mid Cap Value | 3.17% |
| Mid Cap Blend | 0.00 |
| Mid Cap Growth | 14.54% |
| Small Cap Value | 1.25% |
| Small Cap Blend | 2.40% |
| Small Cap Growth | 18.31% |
View More Holdings
As of June 22, 2017
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| CELG | Celgene Corp | 8.33% | 134.31 | +0.47% |
| BIIB | Biogen Inc | 8.07% | 280.32 | -0.09% |
| AMGN | Amgen Inc | 7.98% | 172.50 | -0.76% |
| REGN | Regeneron Pharmaceuticals Inc | 7.85% | 517.33 | -1.75% |
| GILD | Gilead Sciences Inc | 7.74% | 70.52 | +0.06% |
| ALXN | Alexion Pharmaceuticals Inc | 4.16% | 126.07 | -0.13% |
| VRTX | Vertex Pharmaceuticals Inc | 3.91% | 133.50 | -1.50% |
| INCY | Incyte Corp | 3.74% | 136.28 | +0.48% |
| ILMN | Illumina Inc | 3.68% | 185.28 | +1.25% |
| MYL | Mylan NV | 3.07% | 39.03 | +0.05% |
Advertisement
IBB Ratings
| Fiduciary Score | Upgrade |
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Mid Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 1.13 yrs |
| Diane Hsiung | 9.42 yrs |
| Greg Savage | 9.42 yrs |
| Jennifer Hsui | 4.83 yrs |
IBB Net Fund Flows
| 1M | -147.35M |
| 3M | -274.80M |
| 6M | -529.68M |
| YTD | -515.58M |
| 1Y | 827.50M |
| 3Y | 2.004B |
| 5Y | 3.296B |
| 10Y | 3.253B |
IBB Risk Info
| Beta (5Y) | 1.374 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.7284 |
| Historical Sortino (All) | 0.548 |
| 30-Day Rolling Volatility | 19.06% |
| Daily Value at Risk (VaR) 1% (All) | 4.87% |
| Monthly Value at Risk (VaR) 1% (All) | 19.70% |
IBB Fundamentals
| Dividend Yield TTM (6-23-17) | 0.20% |
| SEC Yield (12-31-15) | 0.00% |
| Weighted Average PE Ratio | 20.33 |
| Weighted Average Price to Sales Ratio | 5.800 |
| Weighted Average Price to Book Ratio | 4.731 |
| Weighted Median ROE | 9.70% |
| Weighted Median ROA | -1.98% |
| Forecasted Dividend Yield | 0.62% |
| Forecasted PE Ratio | 18.78 |
| Forecasted Price to Sales Ratio | 4.576 |
| Forecasted Price to Book Ratio | 3.765 |
| Number of Holdings | 164 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 10.42% |
| Forecasted Book Value Growth | 16.82% |
| Forecasted Cash Flow Growth | 16.82% |
| Forecasted Earnings Growth | 13.62% |
| Forecasted Revenue Growth | 15.71% |
IBB Comparables
EditIBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Last Annual Report Date | 3/31/2017 |
| Last Prospectus Date | 8/1/2016 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
